Search

Displaying results 3731 - 3740 of 10000 in total
  1. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. … MKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.).

  2. Drug

    Amorolfine

    go.drugbank.com/drugs/DB09056
    ApprovedWithdrawn

    It is not approved for the treatment of onychomycosis in the United States or Canada. … Amorolfine 5% nail lacquer in once or twice weekly applications is 60-71% effective in treating toenail onychomycosis; complete cure rates three months after stopping treatment (after six months of treatment

  3. Drug

    Pefloxacin

    go.drugbank.com/drugs/DB00487
    Approved

    A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.

  4. Drug

    Lufenuron

    go.drugbank.com/drugs/DB11424
    ExperimentalVet approved

    Lufenuron is used in veterinary for the control of flea.

    Synonyms: N-({[2,5-dichloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]amino}carbonyl)-2,6-difluorobenzamideCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 is an analog of Vitamin B12 labeled with Co60. … Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.

  6. Drug

    Methylergometrine

    go.drugbank.com/drugs/DB00353
    ApprovedInvestigational

    (Merck Index, 11th ed)

    Synonyms: 9,10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamide
  7. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. … TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.

  8. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971 resulted in higher levels of isatoribine in the blood than were present after oral administration of isatoribine itself. … ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection.

  9. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    In preclinical studies to date, PPI-2458 has demonstrated the potent pharmacologic activity of this class of compounds while displaying an improved pharmacokinetic and toxicity profile. … This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases

  10. Drug

    ILY101

    go.drugbank.com/drugs/DB05059
    Investigational

    ILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs. … ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate.